Hansa Biopharma AB (OSTO:HNSA) FCF Margin % : -338.08% (As of Mar. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Hansa Biopharma AB FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Hansa Biopharma AB's Free Cash Flow for the three months ended in Mar. 2024 was kr-189.3 Mil. Hansa Biopharma AB's Revenue for the three months ended in Mar. 2024 was kr56.0 Mil. Therefore, Hansa Biopharma AB's FCF Margin % for the quarter that ended in Mar. 2024 was -338.08%.

As of today, Hansa Biopharma AB's current FCF Yield % is -28.46%.

The historical rank and industry rank for Hansa Biopharma AB's FCF Margin % or its related term are showing as below:

OSTO:HNSA' s FCF Margin % Range Over the Past 10 Years
Min: -10053.6 Med: -2619.62 Max: -327.5
Current: -444.18

During the past 13 years, the highest FCF Margin % of Hansa Biopharma AB was -327.50%. The lowest was -10053.60%. And the median was -2619.62%.

OSTO:HNSA's FCF Margin % is ranked worse than
65.07% of 1045 companies
in the Biotechnology industry
Industry Median: -143.92 vs OSTO:HNSA: -444.18

Hansa Biopharma AB FCF Margin % Historical Data

The historical data trend for Hansa Biopharma AB's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hansa Biopharma AB FCF Margin % Chart

Hansa Biopharma AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-10,053.60

-4,764.97

-1,427.38

-327.50

-563.74

Hansa Biopharma AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
FCF Margin %	Get a 7-Day Free Trial															-857.63	-496.93	-844.54	-342.27	-338.08

Competitive Comparison of Hansa Biopharma AB's FCF Margin %

For the Biotechnology subindustry, Hansa Biopharma AB's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hansa Biopharma AB's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hansa Biopharma AB's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Hansa Biopharma AB's FCF Margin % falls into.

Hansa Biopharma AB FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Hansa Biopharma AB's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-755.938	/	134.094
	=	-563.74 %

Hansa Biopharma AB's FCF Margin for the quarter that ended in Mar. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	-189.259	/	55.981
	=	-338.08 %

Hansa Biopharma AB FCF Margin % Related Terms

Thank you for viewing the detailed overview of Hansa Biopharma AB's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Hansa Biopharma AB (OSTO:HNSA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hansa Biopharma AB (OSTO:HNSA) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

HNSBF:USA 0RC7:UK 24H:Germany

Address

Scheelevagen 22, Lund, SWE, 223 63

Website

https://www.hansabiopharma.com

Hansa Biopharma AB is a biopharmaceutical company that develops immunomodulatory treatments for enabling transplantations and rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection, and cancer. The company's product candidate, imlifidase, is an antibody-cleaving enzyme being developed to enable kidney transplantation in sensitized patients and further developed for use in other organ and tissue transplantation as well as acute autoimmune indications. It operates in Sweden, other European countries, and the U.S. The group generates the majority of its revenue from product sales.

Hansa Biopharma AB (OSTO:HNSA) Headlines

No Headlines